Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes | Zendy

Hanneke M. J. Nijland | Zendy; Rovina Ruslami | Zendy; Janneke E. Stalenhoef | Zendy; Erni Juwita Nelwan | Zendy; Bachti Alisjahbana | Zendy; R.H.H. Nelwan | Zendy; André van der Ven | Zendy; Halim Danusantoso | Zendy; Rob E. Aarnoutse | Zendy; Reinout van Crevel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes

Author(s) -

Hanneke M. J. Nijland,

Rovina Ruslami,

Janneke E. Stalenhoef,

Erni Juwita Nelwan,

Bachti Alisjahbana,

R.H.H. Nelwan,

André van der Ven,

Halim Danusantoso,

Rob E. Aarnoutse,

Reinout van Crevel

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/507543

Subject(s) - medicine , rifampicin , tuberculosis , pharmacokinetics , isoniazid , confidence interval , gastroenterology , geometric mean , diabetes mellitus , metabolite , type 2 diabetes , body mass index , risk factor , endocrinology , pathology , statistics , mathematics

Type 2 diabetes (DM) is a strong risk factor for tuberculosis (TB) and is associated with a slower response to TB treatment and a higher mortality rate. Because lower concentrations of anti-TB drugs may be a contributing factor, we compared the pharmacokinetics of rifampicin in patients with TB, with and without DM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research